Patents Assigned to Pharmacia AS
  • Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
    Patent number: 7354724
    Abstract: The present invention provides a Drosophila melanogaster GPCR (DmGPCR) polypeptides and polynucleotides which identify and encode such a DmGPCR. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of homologs in other animals, and of DmGPCR agonists/antagonists, useful for the treatment of diseases in animals and for the control of insects that are injurious or harmful to plants or animals.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: April 8, 2008
    Assignee: Pharmacia & Upjohn Company
    Inventors: David E. Lowery, Valdin G. Smith, Teresa M. Kubiak, Martha J. Larsen
  • Substituted ureas and carbamates
    Patent number: 7351738
    Abstract: The invention provides compounds of formula I: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: April 1, 2008
    Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
    Inventors: Shon R. Pulley, John A. Tucker
  • Method of treating chronic fatigue syndrome
    Patent number: 7338953
    Abstract: Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual.
    Type: Grant
    Filed: February 7, 2006
    Date of Patent: March 4, 2008
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson
  • 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines
    Patent number: 7338965
    Abstract: The invention relates to substituted piperidine, piperazine, morpholine and thiomorpholine compounds useful in the treatment of Alzheimer's disease and more specifically to compounds that are capable of inhibiting beta-secretase, an enzyme that cleaves amyloid precursor protein to produce amyloid beta peptide (A-beta), a major component of the amyloid plaques found in the brains of Alzheimer's sufferers. One embodiment of the invention relates to compounds having the structure: where Z is CR or N, and R1, R2 and R3 are as described in the specification.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: March 4, 2008
    Assignees: Pharmacia & Upjohn Company, Elan Pharmaceuticals, Inc.
    Inventors: Joseph B. Moon, Shon R. Pulley, Daniel H. Rich, David L. Brown, Barbara Jagodzinska, Varghese John, John Jacobs
  • Infection-resistant medical devices
    Patent number: 7322965
    Abstract: A method for preventing medical device-associated microorganism infection includes the steps of providing a medical device and incorporating an effective amount of an oxazolidinone compound, such as linezolid, into the medical device.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: January 29, 2008
    Assignee: Pharmacia & Upjohn Company
    Inventors: John Kenneth Gibson, Charles W. Ford, Paul J. Pagano
  • Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer
    Patent number: 7320996
    Abstract: The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors of the formula I: wherein R1, R2, R3, R4, R5, R6, and R7 are defined herein, in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: January 22, 2008
    Assignees: Sugen, Inc, Pharmacia Corporation
    Inventors: Jaime Masferrer, Parul Doshi, Julie Cherrington
  • Method of treating peripheral neuropathy
    Patent number: 7317011
    Abstract: Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof. Embodiments of these methods can diminish adverse side effects.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: January 8, 2008
    Assignee: Pharmacia & Upjohn
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert Clyde Marshall, Robert McArthur, Duncan P. Taylor
  • Substituted hydroxyethylamines
    Patent number: 7312360
    Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein the variables G, L, A, W, E, R2, R3, R4, R5, RN, and Rc are defined herein. These compounds interact with and inhibit the activity of the enzyme beta-secretase. These compounds are therefore useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions and methods of treatment of these diseases are also disclosed.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: December 25, 2007
    Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
    Inventors: Ruth TenBrink, Michel Maillard, Martha Warpehoski
  • Retroviral protease inhibitors
    Patent number: 7312333
    Abstract: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: December 25, 2007
    Assignee: Pharmacia Corporation
    Inventors: John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, Kathryn L. Reed, Ko-Chung Lin, John N. Freskos, Michael Clare, Donald J. Rogier, Jr., Robert M. Heintz, Michael L. Vazquez, Richard A. Mueller
  • Transgenic mice knockouts of BACE-1
    Patent number: 7309811
    Abstract: The invention provides transgenic animals that are heterozygous or homozygous for a nonfunctional allele of BACE-1. These animals show normal development indicating that BACE-1 is not necessary for development and hence is an appropriate therapeutic target. The transgenic animals are useful in various screening assays including identifying inhibitors of other enzymes involved in processing of APP to A? and determining a toxicity profile of inhibitors of BACE-1.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: December 18, 2007
    Assignees: Elan Pharmaceuticals, Inc, Pharmacia & Upjohn Company
    Inventors: Lisa McConlogue, Mark E. Gurney
  • Therapeutic compounds
    Patent number: 7291738
    Abstract: The present invention provides compounds, for example, of formula (I): wherein R1, R2, and R3 have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods, and processes and intermediates useful for preparing compounds of formula I.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: November 6, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventor: Jian-Min Fu
  • Method of treating chronic fatigue syndrome
    Patent number: 7276503
    Abstract: Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. Embodiments of these methods can diminish adverse side effects.
    Type: Grant
    Filed: February 7, 2006
    Date of Patent: October 2, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
  • Hydroxypropyl Amides for the Treatment of Alzheimer's Disease
    Publication number: 20070225374
    Abstract: The present invention relates to compounds of formula (I) useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Application
    Filed: November 1, 2004
    Publication date: September 27, 2007
    Applicants: ELAN PHARMACEUTICALS, INC., PHARMACIA & UPJOHN COMPANY LLC
    Inventor: John Tucker
  • Hydroxypropyl amides for the treatment of Alzheimer's disease
    Patent number: 7262208
    Abstract: The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: August 28, 2007
    Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
    Inventors: John A. Tucker, Brian A. Sherer, Ying Zi Xu, Louis Brogley, Shon R. Pulley, Jon S. Jacobs, James P. Beck, Varghese John
  • Benzopyran compounds useful for treating inflammatory conditions
    Patent number: 7259266
    Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: August 21, 2007
    Assignee: Pharmacia Corporation
    Inventors: Jeffry Carter, David Brown, Li Xing, Karl Aston, John Springer, Francis Koszyk, Steven Kramer, Renee Huff, Yi Yu, Bruce Hamper, Subo Laio, Angela Deprow, Teresa Fletcher, E. Ann Hallinan, James Kiefer, David Limburg, Lijuan Wang, Cindy Ludwig, John McCall, John Talley
  • 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors
    Patent number: 7256189
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: August 14, 2007
    Assignees: Sugen, Inc., Pharmacia & Upjohn Company
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu (Alan) Jin, Paul M. Herrinton, Michael A. Mauragis
  • Double mutant alpha-7 nicotinic acetylcholine receptors
    Patent number: 7247706
    Abstract: The invention relates ton novel methods for measuring ion channel transmission and methods and compositions useful in the indentification of ligand gated channel agonists and modulators.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: July 24, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Vincent E. Groppi, Jr., Mitchell B. Berkenpas
  • Salts and polymorphs of a pyrrole-substituted indolinone compound
    Patent number: 7247627
    Abstract: The invention relates to non-hygroscopic salts of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, such as maleate salts, and to crystalline polymorphs of these salts. The invention further relates to pharmaceutical compositions of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide salts, and methods of treating disorders such as cancer using such compositions.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: July 24, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Andrei Blasko, Qingwu Jin, Qun Lu, Michael A. Mauragis, Dian Song, Brenda S. Vonderwell
  • SUBSTITUTED PYRIMIDINONES
    Publication number: 20070167621
    Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: July 14, 2006
    Publication date: July 19, 2007
    Applicant: PHARMACIA CORPORATION
    Inventor: Richard Durley
  • Acetyl 2-hydroxy-1, 3-diaminoalkanes
    Patent number: 7244725
    Abstract: Disclosed are compounds of the formula: where variables Z, X, R15, R2, R3, and RC are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: July 17, 2007
    Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company
    Inventors: Varghese John, Michel Maillard, James P. Beck, Eric T. Baldwin, Robert Hughes, Shon R. Pulley, Ruth TenBrink